Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells.

Ojo EO, Sharma AA, Liu R, Moreton S, Checkley-Luttge MA, Gupta K, Lee G, Lee DA, Otegbeye F, Sekaly RP, de Lima M, Wald DN.

Sci Rep. 2019 Oct 17;9(1):14916. doi: 10.1038/s41598-019-51287-6.

2.

Lipocalin 24p3 Induction in Colitis Adversely Affects Inflammation and Contributes to Mortality.

Liu Z, Cominelli F, Di Martino L, Liu R, Devireddy N, Devireddy LR, Wald DN.

Front Immunol. 2019 Apr 17;10:812. doi: 10.3389/fimmu.2019.00812. eCollection 2019.

3.

Mismatch repair-signature mutations activate gene enhancers across human colorectal cancer epigenomes.

Hung S, Saiakhova A, Faber ZJ, Bartels CF, Neu D, Bayles I, Ojo E, Hong ES, Pontius WD, Morton AR, Liu R, Kalady MF, Wald DN, Markowitz S, Scacheri PC.

Elife. 2019 Feb 13;8. pii: e40760. doi: 10.7554/eLife.40760.

4.

Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.

Ueda M, El-Jurdi N, Cooper B, Caimi P, Baer L, Kolk M, Brister L, Wald DN, Otegbeye F, Lazarus HM, Sandmaier BM, William B, Saunthararajah Y, Woost P, Jacobberger JW, de Lima M.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1122-1127. doi: 10.1016/j.bbmt.2018.12.764. Epub 2018 Dec 30.

PMID:
30599207
5.

Aberrant GSK3β nuclear localization promotes AML growth and drug resistance.

Ignatz-Hoover JJ, Wang V, Mackowski NM, Roe AJ, Ghansah IK, Ueda M, Lazarus HM, de Lima M, Paietta E, Fernandez H, Cripe L, Tallman M, Wald DN.

Blood Adv. 2018 Nov 13;2(21):2890-2903. doi: 10.1182/bloodadvances.2018016006.

6.

Correction: Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.

Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN.

PLoS One. 2018 May 2;13(5):e0197008. doi: 10.1371/journal.pone.0197008. eCollection 2018.

7.

Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.

Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee DA, de Lima M, Wald DN.

PLoS One. 2018 Jan 17;13(1):e0191358. doi: 10.1371/journal.pone.0191358. eCollection 2018. Erratum in: PLoS One. 2018 May 2;13(5):e0197008.

8.

A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.

Hu S, Ueda M, Stetson L, Ignatz-Hoover J, Moreton S, Chakrabarti A, Xia Z, Karan G, de Lima M, Agrawal MK, Wald DN.

Mol Cancer Ther. 2016 Jul;15(7):1485-1494. doi: 10.1158/1535-7163.MCT-15-0566. Epub 2016 May 9.

9.

Repression of GSK3 restores NK cell cytotoxicity in AML patients.

Parameswaran R, Ramakrishnan P, Moreton SA, Xia Z, Hou Y, Lee DA, Gupta K, deLima M, Beck RC, Wald DN.

Nat Commun. 2016 Apr 4;7:11154. doi: 10.1038/ncomms11154.

10.

GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation.

Gupta K, Stefan T, Ignatz-Hoover J, Moreton S, Parizher G, Saunthararajah Y, Wald DN.

Cancer Res. 2016 May 1;76(9):2743-53. doi: 10.1158/0008-5472.CAN-15-2290. Epub 2016 Mar 10.

11.

Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.

Karan G, Wang H, Chakrabarti A, Karan S, Liu Z, Xia Z, Gundluru M, Moreton S, Saunthararajah Y, Jackson MW, Agarwal MK, Wald DN.

Mol Cancer Ther. 2016 Apr;15(4):574-582. doi: 10.1158/1535-7163.MCT-15-0467. Epub 2016 Feb 16.

12.

Wnt signaling is involved in 6-benzylthioinosine-induced AML cell differentiation.

Zang S, Liu N, Wang H, Wald DN, Shao N, Zhang J, Ma D, Ji C, Tse W.

BMC Cancer. 2014 Nov 27;14:886. doi: 10.1186/1471-2407-14-886.

13.

The role of TLR8 signaling in acute myeloid leukemia differentiation.

Ignatz-Hoover JJ, Wang H, Moreton SA, Chakrabarti A, Agarwal MK, Sun K, Gupta K, Wald DN.

Leukemia. 2015 Apr;29(4):918-926. doi: 10.1038/leu.2014.293. Epub 2014 Oct 6.

14.

Impairment of regulatory T-cell function in autoimmune thyroid disease.

Glick AB, Wodzinski A, Fu P, Levine AD, Wald DN.

Thyroid. 2013 Jul;23(7):871-8. doi: 10.1089/thy.2012.0514.

15.

Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance.

Gulen MF, Bulek K, Xiao H, Yu M, Gao J, Sun L, Beurel E, Kaidanovich-Beilin O, Fox PL, DiCorleto PE, Wang JA, Qin J, Wald DN, Woodgett JR, Jope RS, Carman J, Dongre A, Li X.

Immunity. 2012 Nov 16;37(5):800-12. doi: 10.1016/j.immuni.2012.08.019. Epub 2012 Nov 8.

16.

ATP depletion triggers acute myeloid leukemia differentiation through an ATR/Chk1 protein-dependent and p53 protein-independent pathway.

Chakrabarti A, Gupta K, Sharma JP, Yang J, Agarwal A, Glick A, Zhang Y, Agarwal M, Agarwal MK, Wald DN.

J Biol Chem. 2012 Jul 6;287(28):23635-43. doi: 10.1074/jbc.M111.312801. Epub 2012 May 23.

17.

N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy.

Ruhul Amin AR, Thakur VS, Gupta K, Agarwal MK, Wald DN, Shin DM, Agarwal ML.

Oncogene. 2013 Feb 14;32(7):920-9. doi: 10.1038/onc.2012.96. Epub 2012 Mar 19.

18.

GSK3 is a regulator of RAR-mediated differentiation.

Gupta K, Gulen F, Sun L, Aguilera R, Chakrabarti A, Kiselar J, Agarwal MK, Wald DN.

Leukemia. 2012 Jun;26(6):1277-85. doi: 10.1038/leu.2012.2. Epub 2012 Jan 6.

19.

Securinine, a myeloid differentiation agent with therapeutic potential for AML.

Gupta K, Chakrabarti A, Rana S, Ramdeo R, Roth BL, Agarwal ML, Tse W, Agarwal MK, Wald DN.

PLoS One. 2011;6(6):e21203. doi: 10.1371/journal.pone.0021203. Epub 2011 Jun 24.

20.

Sumoylation of vimentin354 is associated with PIAS3 inhibition of glioma cell migration.

Wang L, Zhang J, Banerjee S, Barnes L, Barnes L, Sajja V, Liu Y, Guo B, Du Y, Agarwal MK, Wald DN, Wang Q, Yang J.

Oncotarget. 2010 Nov;1(7):620-7.

21.

p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG.

Thakur VS, Ruhul Amin AR, Paul RK, Gupta K, Hastak K, Agarwal MK, Jackson MW, Wald DN, Mukhtar H, Agarwal ML.

Cancer Lett. 2010 Oct 28;296(2):225-32. doi: 10.1016/j.canlet.2010.04.012. Epub 2010 May 4.

22.

Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells.

Rana S, Gupta K, Gomez J, Matsuyama S, Chakrabarti A, Agarwal ML, Agarwal A, Agarwal MK, Wald DN.

FASEB J. 2010 Jun;24(6):2126-34. doi: 10.1096/fj.09-148999. Epub 2010 Feb 4.

PMID:
20133503
23.

Restoration of p53 functions protects cells from concanavalin A-induced apoptosis.

Amin AR, Thakur VS, Gupta K, Jackson MW, Harada H, Agarwal MK, Shin DM, Wald DN, Agarwal ML.

Mol Cancer Ther. 2010 Feb;9(2):471-9. doi: 10.1158/1535-7163.MCT-09-0732. Epub 2010 Feb 2.

24.

Determination of 6-benzylthioinosine in mouse and human plasma by liquid chromatography-tandem mass spectrometry.

Li L, Xu Y, Wald DN, Tse W.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 15;877(30):3871-7. doi: 10.1016/j.jchromb.2009.09.035. Epub 2009 Oct 1.

PMID:
19836317
25.

Identification of 6-benzylthioinosine as a myeloid leukemia differentiation-inducing compound.

Wald DN, Vermaat HM, Zang S, Lavik A, Kang Z, Peleg G, Gerson SL, Bunting KD, Agarwal ML, Roth BL, Tse W.

Cancer Res. 2008 Jun 1;68(11):4369-76. doi: 10.1158/0008-5472.CAN-07-6559.

26.

Measuring the clinical impact of pathologist reviews of blood and body fluid smears.

Sandhaus LM, Wald DN, Sauder KJ, Steele EL, Meyerson HJ.

Arch Pathol Lab Med. 2007 Mar;131(3):468-72.

PMID:
17516750

Supplemental Content

Support Center